| scholarly article | Q13442814 |
| P2093 | author name string | Meir Wetzler | |
| Omar Al Ustwani | |||
| P2860 | cites work | Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia | Q28257174 |
| Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) | Q33758413 | ||
| Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia | Q34154708 | ||
| Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia | Q34536382 | ||
| Omacetaxine as an anticancer therapeutic: what is old is new again | Q34626798 | ||
| Adult acute myeloid leukaemia. | Q35795579 | ||
| A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. | Q36612188 | ||
| Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice | Q37303829 | ||
| Cephalotaxine esters: antileukemic advance or therapeutic failure? | Q39519143 | ||
| Homoharringtonine--perspectives on an active new natural product | Q39743946 | ||
| Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype | Q43927958 | ||
| CHAG priming regimen containing of cytarabine, aclacinomycin homoharringtonine and G-CSF for relapsed refractory acute myelogenous leukemia: a modified combination chemotherapeutic combination. | Q45910107 | ||
| Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial | Q46949702 | ||
| Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. | Q54450912 | ||
| P433 | issue | 10 | |
| P921 | main subject | acute myeloid leukemia | Q264118 |
| P304 | page(s) | 2100-2102 | |
| P577 | publication date | 2013-03-27 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | Homoharringtonine and granulocyte colony-stimulating factor priming for acute myeloid leukemia: is it ready for prime time? | |
| P478 | volume | 54 |
| Q46316687 | Cephalotaxus Alkaloids | cites work | P2860 |
Search more.